Century Therapeutics (IPSC) Total Debt (2020 - 2026)

Century Therapeutics (IPSC) posted quarterly Total Debt of $1.9 million for Q1 2026, down 48.39% quarter-over-quarter from $3.8 million in Q4 2025.

Century Therapeutics (IPSC) Total Debt (2020 - 2026) Analysis & Trends

Century Therapeutics (IPSC) has reported Total Debt for 6 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.

In Q1 2026, Total Debt changed N/A year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (changed N/A YoY), while the FY2025 annual figure was $3.8 million, changed N/A from the prior year.
Total Debt declined to $1.9 million in Q1 2026 per IPSC's latest filing, from $3.8 million in the prior quarter.
Across five years, Total Debt topped out at $10.3 million in Q1 2023 and bottomed at $1.9 million in Q1 2026.
Historically, Total Debt has averaged $8.1 million across 4 years, with a median of $10.1 million in 2022.
Annual changes were most pronounced in 2022 — Total Debt advanced 3.01% — and 2023, when it advanced 2.78%.
Century Therapeutics' Total Debt stood at $10.2 million in 2022, then rose by 0.55% to $10.3 million in 2023, then plunged by 63.51% to $3.8 million in 2025, then slumped by 48.39% to $1.9 million in 2026.
Business Quant data shows IPSC's Total Debt at $1.9 million in Q1 2026, $3.8 million in Q4 2025, and $8.3 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.07 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	9.34 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	Century Therapeutics	346.65 Mn	86.58 Mn	-	-

Download Data